Skip To Main Content
Ying Cheng on Muck Rack

Ying Cheng

As seen in: Arthritis & Rheumatology, Color Research & Application, Nature, Wiley, Wiley Online Library, PLOS ONE, Educational Studies, Frontiers, Frontiers in Public Health, MDPI and
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Ying

Contact Ying, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Ghrelin Alleviates Aging-Related Cognitive Impairment by Regulating Autophagy-Related Signaling via the SHBG/JNK1/Beclin1 Axis in Microglia

|
By Lixing Zhou, Ying Cheng, Wanyu Zhao
| Wiley Online Library Verified
1 Introduction Cognitive impairment (CI) is a prevalent, age-related condition characterized by progressive deficits in memory, attention, and executive functions that impair activities of daily living (Gordon and Martin 2013; Tangalos and Petersen 2018). CI is clinically stratified from mild cognitive impairment (MCI), which represents an intermediate state between normal aging and dementia, to more severe forms associated with Alzheimer's disease and vascular dementia (Gordon and Martin 2013).
Open in Who Shared Issue with article?

Espanyol: gramàtica básica

|
By Yun Cheng, Ying Cheng
| Dialnet - Universidad de La Rioja
IdiomacatalàDeutschEnglishespañoleuskarafrançaisgalegoitalianoportuguêsromână
Open in Who Shared View Duplicates (686) Issue with article?

Disitamab vedotin for HER2-positive breast cancer with liver metastases: phase 3 results from the RC48-C006 phase 2/3 trial

|
By Jiayu Wang, Quchang Ouyang, Weimin Xie, Zhaofeng Niu, Qingyuan Zhang, Jianying Chang, Ying Cheng, Airong Wang, Jingfen Wang, Herui Yao, Tao Lin Sun, Zhongsheng Tong, Xinhong Wu, Yongsheng Wang, Enxiang Zhou, Xiangshun Kong, De Zeng, Shanshan Gu, Yanyan Hou, Dandan Gao, Jianmin Fang, Binghe Xu, Yue’e Teng, Zhuangqing Yang, Xujuan Wang, Zerui Qu, Chenran Han
| Nature Verified
Abstract Patients with HER2-positive advanced breast cancer with liver metastases (BCLM) have poor prognosis. Study RC48-C006 is a prospective, open-label, multi-center, randomized phase 2/3 trial (ClinicalTrials.gov identifier, NCT03500380). Based on the phase 2 results, the phase 3 stage was initiated to evaluate disitamab vedotin (DV) versus lapatinib plus capecitabine (L + C) in patients with HER2-positive BCLM who were previously treated with trastuzumab and taxanes.
Open in Who Shared Issue with article?
See all 158 licensed articles (164 Total)